No Data
No Data
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Has Caught the Attention of Institutional Investors Who Hold a Sizeable 46% Stake
Leerink Partners Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Announces Target Price $8
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)
Analysts Are Bullish on These Healthcare Stocks: Biomea Fusion (BMEA), Eledon Pharmaceuticals (ELDN)
Guggenheim Remains a Buy on Eledon Pharmaceuticals (ELDN)
We're Hopeful That Eledon Pharmaceuticals (NASDAQ:ELDN) Will Use Its Cash Wisely